The study, labeled QoliXane, has enrolled about 350 patients and data from the study are currently being collected. In an interview with Targeted Oncology, Gerrit zur Hausen, MD, clinical trial manager, epidemiologist, Krankenhaus Nordwest GmbH, discusses the importance of uncovering the quality of life for these patients, how interventional therapies play a role in their quality of life, and the management of toxicities that may arise from these drugs. Read more . . .